<DOC>
	<DOC>NCT00441610</DOC>
	<brief_summary>CLBQ707A1101 assesses the tolerability, safety, efficacy and pharmacokinetics of gimatecan in Japanese patients.</brief_summary>
	<brief_title>An Extension Trial to a Phase I Dose Escalation Study of Gimatecan Administered Orally 5 Consecutive Days to Japanese Patients With Advanced Solid Tumor</brief_title>
	<detailed_description />
	<mesh_term>Camptothecin</mesh_term>
	<criteria>Inclusion criteria: Patients completing the core protocol (CLBQ707A1101, NCT00410358) exhibiting stable disease, or a partial or complete response as defined by the core protocol. If patients only have nonmeasurable lesions, he/she must not be exhibiting progressive disease Exclusion criteria: Documented progressive disease as defined by the core protocol Patients with performance status of 3 or 4 on the ECOG scale Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Gimatecan</keyword>
	<keyword>topoisomerase I inhibitor</keyword>
	<keyword>advanced solid tumors</keyword>
</DOC>